All News

RheumNow Podcast square

RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.

Read Article
FDA.Not_.jpg

FDA Panel Rejects Tanezumab for Osteoarthritis

d Jack Cush, MD

A two day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab, a nerve growth factor inhibitor, for use in osteoarthritis (OA).

Read Article
The Reflecting Rheum: 2020 SpA and Still’s Disease Highlights Sponsored by Novartis Medical Affairs Listen to a discussion of medical experts share their views on the most impactful work done in spondyloarthritis and Still’s disease in 2020. https://t.co/Kp2drDAqFv https://t.co/6oOGSq0Psl

Links:

Dr. John Cush RheumNow ( View Tweet)
QD147 Pain, but No Pain Meds QD Clinic - Lessons from the clinic Why Pain Consults present Not Taking Pain Meds Features Dr. Jack Cush https://t.co/yRNh6QraED

Links:

Dr. John Cush RheumNow ( View Tweet)

Potent Topical Corticosteroids and the Risk of Osteoporotic Fractures https://t.co/OHohMKveik

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2021 Thanks @uptoTate https://t.co/VKFodPOwgC

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2021 coverage by @uptoTate for #RheumNow https://t.co/x1GjGGNPii

Links:

Dr. John Cush RheumNow ( View Tweet)

Great #RNL2021 coverage by @KDAO2011 for #RheumNow https://t.co/GBnlyvPaz1

Links:

Dr. John Cush RheumNow ( View Tweet)

Liver Management in RA - #RNL2021 Highlight by @DrPetryna While RA is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the mgmt of many RA patients. https://t.co/OeuloDIXMF

Links:

Dr. John Cush RheumNow ( View Tweet)

New RheumNow Podcast Now Available! Infection in ANCA-Associated Vasculitis https://t.co/Twy04G9RU1 Download wherever podcasts are available!

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast – Infection in ANCA-Associated Vasculitis Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on https://t.co/4GKxMY5Lll https://t.co/joi1puBSuX

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2021 coverage from @KDAO2011 #RheumNow https://t.co/GBnlyvPaz1

Links:

Dr. John Cush RheumNow ( View Tweet)

Are You a Super Rheum? https://t.co/omvQXwhcoV https://t.co/8iQaRAi5di

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis of CPRD registry and 15670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY; half that after Yr 1 (22 & 2.84). D/C for severe labs was 1 in 169 Yr1 & 1 in 352 per year after https://t.co/Dx91YqjplT

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2021 Highlights: Future Therapeutics for Rheumatoid Arthritis and Lessons Learned https://t.co/NxLyHeI2f4 https://t.co/df7lPEia0D

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: FDA Panel Rejects Tanezumab for Osteoarthritis A 2 day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab for use in OA. https://t.co/ltKmm9Nl1y https://t.co/qTWhSX9LBd

Links:

Dr. John Cush RheumNow ( View Tweet)
The Reflecting Rheum: Top Publications from 2020 Covering SpA and Still’s Disease Sponsored by Novartis Medical Affairs Listen to a panel of experts share their views on top spondyloarthritis and Still’s disease publications from 2020. View Now: https://t.co/Kp2drDAqFv https://t.co/tjkUpxcMdT

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2021 coverage from @uptoTate #RheumNow https://t.co/u11ltNc2vA

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow podcast is up--Great Associations Dr. Jack Cush rants on the journal reports, news and FDA actions featured last week on RheumNow. https://t.co/gzWVbL8xMJ

Links:

Dr. John Cush RheumNow ( View Tweet)

Claims data analysis (MarketScan, Medicare, Optum) of 87,653 RA patients starting either TNF inhibitor or tofacitinib shows venous thromboembolism (VTE) is rare (<1 per 100) RA Rx with either. VTE risk was same for Tofa and TNFi (HR of 1.13 [0.77-1.65]) https://t.co/UoMQRp12vo

Links:

Dr. John Cush RheumNow ( View Tweet)

×